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INTRODUCTION
Familial adenomatous polyposis (FAP) is a hereditary
condition transmitted in an autosomal dominant fashion,
which is characterized by the appearance of numerous
adenomatous polyps in the colon. This condition results
from mutation of the APC gene and accounts for 1% of cases
of colorectal cancer.1
FAP is frequently associated with extracolonic manifesta-
tions: desmoid tumors, osteomas, pigmented lesions of the
retina, adenomas of the upper gastrointestinal tract, and
epidermoid cysts, as well as gastric, thyroid, suprarenal,
and central nervous system cancer.2
The desmoid tumor (DT) is a benign neoplasm that occurs
in 10%–20% of the patients with FAP. It originates from
fascial or muscle-aponeurotic structures that foster fibro-
blast proliferation. DTs occur more frequently in the intra-
abdominal region or the abdominal wall, although they can
also be detected in extra-abdominal areas. It is a rare type of
tumor, representing 0.03% of neoplasms. Compared with
the general population, a patient with FAP is at an 852-fold
increased risk of developing a DT.3
Although benign from a histological viewpoint, a DT can
display aggressive biological behavior characterized by
infiltrative growth and a high recurrence rate after resection.
DTs represent the second most common cause of death in
patients with FAP.
CASE REPORT
This is a report on a female patient, aged 29 years, who
presented with hematochezia for one year and had a family
history of FAP (mother with FAP, submitted to surgery).
Colonoscopy revealed numerous polyps measuring between
0.2 and 2 cm along the colon and rectum, which confirmed
FAP. The patient underwent total proctocolectomy and
terminal ileostomy because of the presence of neoplastic
tissue (T2N1M0) in the rectum. She received adjuvant
chemotherapy with 5-fluorouracil and leucovorin. A year
later, she was subjected to reconstruction of the intestinal tract
with a J-shaped ileal reservoir and protective ileostomy loop.
Subsequently, she was diagnosed with thyroid papillary
carcinoma and was submitted to total thyroidectomy and
iodine therapy. Upon clinical examination, abdominal palpa-
tion revealed a hard mass in the mesogastrium. Computed
tomography and magnetic resonance imaging examinations
revealed two masses, one in the mesogastrium (8.56
5.863 cm) (Figure 1) and the other in the region anterior to
the sacrum (6.565.4 cm) (Figure 2).
The patient underwent exploratory laparotomy, which
detected a large solid mass involving the mesentery and
omentum, with peritoneal infiltration, which did not allow for
total excision. The patient progressed satisfactorily, and the
anatomopathological findings confirmed a DT. Chemothe-
rapy with doxorubicin 75 mg/m2 was performed every 21
days for six months. The patient’s progress on chemotherapy
was assessed by abdominal computerized tomography. There
abdominal mass displayed no progression and remained
clinically stable at the 12-month follow-up.
DISCUSSION
Colorectal cancer and DTs are the main causes of death
among patients with FAP. The association of DTs and FAP
occurs in patients with Gardner’s Syndrome. DTs and FAP
have been described in 3.5% to 5.7% of the patients with this
syndrome, although they can also occur in the absence of
the syndrome.4,5 The association of FAP, thyroid papillary
carcinoma, and a DT found in the present case is a clinical
variation of Gardner’s syndrome.
In some cases, DT diagnosis may precede FAP diagnosis,
because the DT may develop in abdominal incisions
performed for other purposes, such as appendectomy.6,7
Although composed of benign fibromatous lesions, DTs
display aggressive behavior. They consist of encapsulated,
slow-growing, locally aggressive tumors with infiltrative
growth in adjacent tissues. The outcome is unpredictable. In
some circumstances, they remit spontaneously, whereas in
most cases, they grow implacably, culminating in death.
Seventy percent of all DTs are intra-abdominal, but the
mesentery is frequently involved as well.8 DTs also occur in
the retroperitoneum, abdominal wall (incisions), inguinal
region, and gluteus. Sometimes, they are multifocal.
The presence of a palpable mass in patients with FAP
should lead physicians to suspect a DT. Small DTs may be
asymptomatic. Symptoms are generally related to adjacent
organ compression, as well as urethral obstruction, intest-
inal obstruction, bowel ischemia and perforation, or even
aortic rupture.8,9 The 10-year survival of patients with intra-
abdominal tumors can be as high as 60% to 70%; death
occurs six years after diagnosis, on average.10,11
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The occurrence of DTs is associated with different risk
factors, such as female reproductive age, use of oral
contraceptives (OCC), and pregnancy. The larger preva-
lence of DTs in these cases, as well as their rare occurrence
before menarche and after menopause, is related to the
influence of female sex hormones on tissues. Estrogen
receptor counts in neoplastic tissues from women with DTs
are significantly higher than those in normal tissues.
Evidence that the in vitro proliferation of desmoid cells is
inhibited by antiestrogen drugs suggests a strong relation-
ship between estrogen levels and DT development.12-14
Other risk factors for DTs include previous surgery and a
family history of DTs. The mechanism through which
surgical trauma predisposes individuals to DTs remains
unclear, but approximately 80% of patients with this tumor
have already undergone previous abdominal surgeries.
Patients with FAP have a 16% cumulative risk of developing
DT in the ten years subsequent to colectomy, and this tumor
usually appears between one and three years following
colorectal surgery. The manifestation of this tumor does not
seem to be associated with a specific surgery type because it
is equally incident in patients that have been submitted to
proctocolectomy with ileal pouch, ileal-rectum, or ileal-
sigmoid anastomosis and in individuals subjected to partial
colectomy.12,10,15 Patients with FAP and a family history of
DTs are at a 25% increased risk of developing DTs.15
Surgery, radiotherapy, and chemotherapy are some of the
approaches used to treat DTs. The treatment of choice is
total resection with a safety margin. DT recurrence rates
after resection lie between 60% and 85%. Less invasive
surgeries are associated with fewer postoperative complica-
tions and lower recurrence rates, whereas more invasive
surgeries are correlated with higher morbidity. Therefore,
bypass procedures are usually preferred over resection for
the correction of obstructions.8,9,15
Because of the possibility of recurrence and prolonged
survival, some authors recommend that DT patients with
mild symptoms should be kept under supervision only.
The use of noncytotoxic drugs, such as nonsteroidal anti-
inflammatory drugs (sulindac, indomethacin) and antiestro-
gen agents (tamoxifen, progesterone), has proven to be
beneficial for DT patients, with reduction in tumor size and
symptomatology compared with nontreated patients. The
objective response rate for each of these agents is 50%.
Seventy-nine percent of DTs present specific receptors for
antiestrogen drugs. Some authors have suggested that intra-
abdominal DT should be treated with 150 mg of sulindac
twice a day. If the tumor continues to grow, tamoxifen can
be administered at 80 mg/day.16-19
Cytotoxic chemotherapeutic drugs employed in the
treatment of sarcoma (e.g., doxorubicin and carboplatin)
are restricted to symptomatic patients with unresectable and
Figure 1 - Computed tomography showing a huge mass in the mesogastrium.
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clinically aggressive tumors or with tumors that do not
respond to other therapies,15,20,21 as reported in this case.
The role of radiotherapy in the treatment of DTs involving
the abdominal wall, either as adjuvant therapy or primary
treatment, is advancing. Higher local control rates have
been achieved by employing surgery associated with
radiotherapy, as compared with surgery alone, especially
when tumor resection is incomplete. As for intra-abdominal
tumors, the use of radiotherapy is still limited because of
potential complications, such as actinic enteritis.22
FAP does not occur only in the colon; indeed, the
incidence of extracolonic manifestations can be as high as
40%. Hence, research, prevention, and the treatment of FAP
manifestations are important. In this context, the identifica-
tion of patients at risk of developing DTs is crucial for the
design of prevention strategies. Moreover, it is mandatory
that patients are aware of the need for periodic evaluations
and that they are warned about the risk of extracolonic
manifestations and their impact on the quality of life.
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